CDK12 and prostate carcinoma: Antonarakis et al. [61] revealed early results of a multi-institution retrospective study of 60 men with CDK12-altered prostate cancers that showed 0 of the 11 who received PARPis (10 olaparib, 1 rucaparib) had a PSA response.